Herbalife (HLF) Q2 2026 earnings review
Topline Growth Continues, But Margins and Regional Rot Weigh on Results
Herbalife delivered its fourth consecutive quarter of YoY revenue growth (+5.4%), hitting the top end of its guidance. However, the quality of this growth is heavily bifurcated. Surging sales in Asia Pacific and Latin America are masking a severe collapse in China (-24.5%) and weakness in EMEA. Bottom-line results were noisy, hindered by a $94.6 million debt extinguishment charge tied to an April refinancing, resulting in a net loss of $26.3 million. Even adjusting for this, Adjusted EBITDA margins compressed 120 basis points to 12.6%. While management raised constant-currency EBITDA guidance, a strong US dollar forced a cut to the reported FY26 EBITDA outlook.
🐂 Bull Case
The successful April 2026 debt refinancing eliminates near-term maturity risks, locking in a more stable capital structure and generating expected annual cash interest savings of ~$45 million, providing critical flexibility for their digital pivot.
Asia Pacific (+15.2% YoY) and Latin America (+16.6% YoY) are providing a massive growth floor. If these regions maintain momentum while the US and EMEA stabilize via new product launches, the top-line trajectory is highly secure.
🐻 Bear Case
The turnaround in China has completely stalled out. Sales plummeted 24.5% YoY (29% in constant currency), reflecting deep structural or execution issues that are actively destroying consolidated growth.
Gross margins are compressing (down 30 bps YoY) due to unfavorable sales mix, higher other costs, and inventory write-downs. Persistent FX headwinds are actively destroying adjusted EBITDA output, forcing a cut to full-year reported profit guidance.
⚖️ Verdict: ⚪
Neutral. The company is successfully returning to volume and revenue growth, and the debt refinancing is a massive de-risking event. However, the geographic bifurcation and persistent margin degradation demand caution until the Pro2col/Bioniq investments prove they can yield high-margin recurring revenue.
Key Themes
China's Unrelenting Collapse
China is acting as an aggressive anchor on global results. Sales dropped 24.5% YoY in Q2 to $60.4M, accelerating its deceleration from -12% in Q1 2026 and -4.4% in Q4 2025. On a constant currency basis, the drop was even more severe at -29.0%. Management must address whether this market is structurally broken for the direct-selling model or if it's purely an execution failure.
Latin America and Asia Pacific Heavy Lifting
The consolidated 5.4% sales growth was overwhelmingly driven by two regions. Latin America surged 16.6% YoY to $245M, while Asia Pacific jumped 15.2% to $470.6M. These segments are accelerating robustly, compensating for the stagnation in North America (+0.2%) and declines in EMEA and China.
Profitability Squeezed by Mix and Macro FX
Despite revenue outperformance, profitability is weakening. Gross margins fell to 77.7% (down ~30 bps), driven by 47 bps of sales mix pressure and 20 bps from higher inventory write-downs. Furthermore, a strengthening US dollar sliced $7.6M off Q2 Adjusted EBITDA, forcing management to lower the midpoint of their reported FY26 EBITDA guidance by $10M despite raising the constant-currency outlook.
Aggressive Push into Hyper-Personalization
Herbalife is aggressively rolling out its personalized product suite. They launched Bioniq GO—matching customers to 40 different formulas—across 11 EMEA markets and North America. Simultaneously, the company unveiled an extended beta of its Pro2col platform, which uniquely integrates blood-test diagnostics for distributors. This marks a massive shift from mass-market powders to customized, data-driven wellness.
Portfolio Expansion to Capture Lifespan Market
The company introduced 'Helio' (an all-in-one super shake) and 'Activate Energy' (exogenous ketones from the Prüvit acquisition) under their new 'Life I/O' brand. These channel-exclusive entries target modern wellness trends, moving beyond traditional weight loss to target longevity and cognitive/physical performance.
C-Suite Transition
CFO John DeSimone will retire at the end of 2026, handing the reins to Scott Schaefer. DeSimone was architect of the recent debt restructuring that saved the balance sheet. Investors will look to Schaefer to maintain the strict deleveraging discipline while funding the expensive digital rollout.
Other KPIs
Decelerating. Down from $175.7M in Q1 2026 and $173.6M in Q2 2025. Margin compressed 120 bps year-over-year to 12.6%. The drop was driven by sales mix, inventory write-downs, and a $7.6M FX headwind, completely offsetting the benefit of 64 bps in favorable pricing actions.
Accelerating significantly compared to $96.2 million in the first half of 2025. Working capital management remains a bright spot, providing ample coverage for $22.2M in CapEx and $18M in capitalized SaaS software implementation costs.
A massive one-time hit to the income statement resulting from the April 2026 refinancing. While painful on a GAAP basis, this transaction pushed out near-term maturities to 2031/2033 and is expected to save the company $45 million annually in cash interest.
Guidance
Decelerating from Q2's actual growth of 5.4%. Constant currency guidance is slightly better (+1.5% to +5.5%), signaling that management anticipates FX to remain a persistent drag into the back half of the year.
Stable to slightly Accelerating. The company tightened the range upward (previously +1.5% to +5.5%), signaling confidence that the volume turnaround is sustainable, heavily supported by Asia Pacific and LatAm.
Decelerating vs. prior expectations. Management lowered the guidance range from $675-$705 million entirely due to a strong US dollar. Notably, the constant currency EBITDA guidance was actually raised to $690-$710 million, indicating core operational outperformance being masked by macro FX.
Key Questions
China's Bottom
With China sales down nearly 25% year-over-year in Q2, where do you see the floor for this segment? Are there any restructuring actions planned to stop the bleeding, or is the market structurally impaired?
Pro2col and Bioniq Economics
As Bioniq GO and the Pro2col diagnostic integrations roll out, how do the gross margin and customer acquisition costs for these personalized, subscription-based offerings compare to your traditional product portfolio?
Capital Allocation Under New CFO
With John DeSimone retiring at year-end, will Scott Schaefer maintain the exact same framework prioritizing debt reduction to $1.4B by 2028, or might we see a shift toward share repurchases given the recent refinancing success?